DCAF4L2

Across TCGA pan-cancer cohorts, DCAF4L2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCAF4L2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DCAF4L2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated DCAF4L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LIHC, and BLCA are the cancer types where DCAF4L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.949	0.608	.007	26	view →
LIHC	DFS	Median	All	0.081	0.548	<.001	24	view →
BLCA	OS	Median	All	0.210	0.619	.010	9	view →
PCPG	DFS	Median	All	0.088	0.768	.002	6	view →
SKCM	OS	Median	III,IV	0.264	0.729	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCAF4L2–UCEC (DFS)

Open the UCEC breakdown →